CymaBay Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants.
NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay sold 14,521,307 shares of common stock in the offering, including 1,970,227 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $17.13 per share. In addition, CymaBay sold, in lieu of common stock to certain investors, pre-funded warrants to purchase 583,771 shares of common stock in the offering at a public offering price of $17.1299 per underlying share. The gross offering proceeds to CymaBay from this offering were approximately $258.7 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. The pre-funded warrant has an exercise price of $0.0001 per share. All shares of common stock and pre-funded warrants were offered by CymaBay.
CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.
Piper Sandler, Raymond James, Cantor and LifeSci Capital acted as the joint book-running managers for the offering. BTIG acted as the lead manager for the offering.
The securities described above were offered by CymaBay pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). A final prospectus supplement and the accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com; Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by e-mail at prospectus@raymondjames.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com; or LifeSci Capital LLC, Attention: Syndicate Prospectus Department, 250 West 55th Street, 34th Floor, New York, NY 10019, by email at compliance@lifescicapital.com or by telephone at (646) 876-5059.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CymaBay
CymaBay Therapeutics, Inc. (Nasdaq: CBAY) is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies.
Cautionary Statements
This press release contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the anticipated use of proceeds. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to the success, cost and timing of CymaBay’s product development activities, including clinical trials. Additional risks and uncertainties relating to CymaBay and its business can be found in the “Risk Factors” section of CymaBay’s Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 10, 2023, and in the final prospectus supplement related to the offering filed with the SEC on September 12, 2023. CymaBay undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in CymaBay’s expectations.
Public Relations Contact:
Theresa Dolge
Evoke Kyne
(609) 915-2156
Theresa.Dolge@evokegroup.com
Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com
